Participants in the Remission from Chronic Opioid Use, Studying Environmental and SocioEconomic Factors on Recovery (RECOVER; ClinicalTrials identifier: NCT03604861) study reported positive outcomes, including high opioid abstinence, according to findings published in the Journal of Addiction Medicine.
Efforts to combat the opioid epidemic have primarily focused on the promotion of overdose-reversing medications. However, little is known about the long-term outcomes of pharmacotherapy for opioid use disorder (OUD). In this 24-month observational study, researchers sought to capture 12-month outcomes from individuals who had previously participated in a buprenorphine extended-release subcutaneous injection (BUP-XR) trial.
Participants were asked to complete detailed self-administered assessments concerning substance use, treatment for substance use disorder, and psychosocial measures. Researchers assessed sustained opioid abstinence over the course of 12 months and self-reported past-week abstinence at 3-, 6-, 9-, and 12-month visits. In addition, pain, withdrawal, health-related quality of life, employment, and depression at RECOVER baseline and 12-month visits were compared with values collected before treatment in the BUP-XR trial.